BioMarin Pharmaceuticals (BMRN) Misses Q4 EPS by 12c; Guides FY12 Revs Below
Tweet
Share
E-mailGet Alerts BMRN Hot Sheet
Price: $57.17 -0.28%
EPS Growth %: -34.0%
Financial Fact:
Research and development: 160.83M
Today's EPS Names:
DTGI, CRMT, MAYS, More
EPS Growth %: -34.0%
Financial Fact:
Research and development: 160.83M
Today's EPS Names:
DTGI, CRMT, MAYS, More
Join SI Premium – FREE
BioMarin Pharmaceuticals, Inc. (NASDAQ: BMRN) reported Q4 EPS of ($0.23), $0.12 worse than the analyst estimate of ($0.11). Revenue for the quarter came in at $107.9 million versus the consensus estimate of $115.3 million.
Sees FY2012 revenue of $465-$510 million, versus the consensus of $512.6 million.
For earnings history and earnings-related data on BioMarin Pharmaceuticals, Inc. (BMRN) click here.
Sees FY2012 revenue of $465-$510 million, versus the consensus of $512.6 million.
For earnings history and earnings-related data on BioMarin Pharmaceuticals, Inc. (BMRN) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- SanDisk stock target lifted by Citi on continued demand strength
- MillerKnoll, Inc. (MLKN) Tops Q4 EPS by 4c
- BlackBerry (BB) Tops Q1 EPS by 1c, Offers Guidance
Create E-mail Alert Related Categories
Earnings, Guidance, Hot GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
